Capital investments in production plants represent a significant portion of the cost of new recombinant drugs
Harry M. Meade
Advertisement
Harry M. Meade, PhD, is senior vice president of research and development at GTC Biotherapeutics, Inc.
Articles by Harry M. Meade
Advertisement
Latest Updated Articles
Advertisement
Advertisement